Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver

被引:34
作者
Roglans, N
Bellido, A
Rodríguez, C
Cabrero, A
Novell, F
Ros, E
Zambón, D
Laguna, JC
机构
[1] Univ Barcelona, Fac Pharm, Pharmacol Unit, E-08028 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin & Prov, Dept Surg, Barcelona, Spain
[3] Univ Barcelona, Hosp Clin & Prov, Lipid Clin, Nutr & Dietet Serv, Barcelona, Spain
[4] Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
关键词
D O I
10.1067/mcp.2002.128605
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and objectives: Fibrates induce hepatic peroxisome proliferation and carcinogenesis in rodents by activating peroxisome proliferator-activated receptor alpha (PPARalpha). There is no conclusive evidence that humans are unresponsive to peroxisome proliferation, and concern exists about the long-term safety of fibrate treatment. Methods: In a university hospital setting, 48 patients with uncomplicated gallstones and a serum level of low-density lipoprotein cholesterol greater than 130 mg/dL were randomly assigned to open-label treatment with bezafibrate (400 mg/d), fenofibrate (200 mg/d), gemfibrozil (900 mg/d), or placebo for 8 weeks before elective cholecystectomy. Serum samples for lipid determinations were obtained at baseline and before surgery. A liver specimen was obtained at operation, and the relative levels of messenger ribonucleic acid (mRNA) for the wild and truncated forms of PPARalpha, acyl coenzyme A oxidase, liver carnitine palmitoyltransferase I, apolipoprotein A-I, and stearoyl coenzyme A desaturase were determined. Results. Fenofibrate, bezafibrate, and gemfibrozil reduced plasma low-density lipoprotein cholesterol levels by 22% (P=.009), 14% (P=.042), and 11% (not significant), respectively. Plasma triglyceride levels decreased significantly (24%-36%; P<.05), whereas high-density lipoprotein cholesterol levels rose non-significantly after treatment with the 3 fibrates. Except for a 35% increase of apolipoprotein A-I mRNA after fenofibrate administration (P<.05), none of the individual fibrates induced significant changes in the mRNAs tested, although as a group they increased the mRNA for liver carnitine palmitoyltransferase I by 40% (P=.08; marginally significant). Conclusions: Fibrate administration to humans at pharmacologic doses able to activate PPARalpha and to induce a hypolipidemic effect does not increase the hepatic expression of acyl coenzyme A Oxidase, a well-known marker of peroxisome proliferation in rodents.
引用
收藏
页码:692 / 701
页数:10
相关论文
共 38 条
  • [1] SELECTIVE MODIFICATION OF RAT HEPATIC-MICROSOMAL FATTY-ACID CHAIN ELONGATION AND DESATURATION BY FIBRATES - RELATIONSHIP WITH PEROXISOME PROLIFERATION
    ALEGRET, M
    CERQUEDA, E
    FERRANDO, R
    VAZQUEZ, M
    SANCHEZ, RM
    ADZET, T
    MERLOS, M
    LAGUNA, JC
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (07) : 1351 - 1358
  • [2] Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits
    Alegret, M
    Verd, JC
    Díaz, C
    Hernández, G
    Adzet, T
    Sánchez, RM
    Laguna, JC
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 347 (2-3) : 283 - 291
  • [3] BALUUBOER BJ, 1990, BIOCHEM PHARMACOL, V40, P521
  • [4] Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice
    Berthou, L
    Duverger, N
    Emmanuel, F
    Langouet, S
    Auwerx, J
    Guillouzo, A
    Fruchart, JC
    Rubin, E
    Denefle, P
    Staels, B
    Branellec, D
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) : 2408 - 2416
  • [5] EFFECTS OF DIFFERENT PHENOTYPES OF HYPERLIPOPROTEINEMIA AND OF TREATMENT WITH FIBRIC ACID-DERIVATIVES ON THE RATES OF CHOLESTEROL 7-ALPHA-HYDROXYLATION IN HUMANS
    BERTOLOTTI, M
    CONCARI, M
    LORIA, P
    ABATE, N
    PINETTI, A
    GUICCIARDI, ME
    CARULLI, N
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (08) : 1064 - 1069
  • [6] BURSTEIN M, 1970, J LIPID RES, V11, P583
  • [7] Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
    Cattley, RC
    DeLuca, J
    Elcombe, C
    Fenner-Crisp, P
    Lake, BG
    Marsman, DS
    Pastoor, TA
    Popp, JA
    Robinson, DE
    Schwetz, B
    Tugwood, J
    Wahli, W
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1998, 27 (01) : 47 - 60
  • [8] Peroxisome proliferator-activated receptors: Nuclear control of metabolism
    Desvergne, B
    Wahli, W
    [J]. ENDOCRINE REVIEWS, 1999, 20 (05) : 649 - 688
  • [9] CONTROL OF THE PEROXISOMAL BETA-OXIDATION PATHWAY BY A NOVEL FAMILY OF NUCLEAR HORMONE RECEPTORS
    DREYER, C
    KREY, G
    KELLER, H
    GIVEL, F
    HELFTENBEIN, G
    WAHLI, W
    [J]. CELL, 1992, 68 (05) : 879 - 887
  • [10] EINARSSON K, 1986, ATHEROSCLER REV, V15, P67